Skip to content

Ultrasound assessment of radiochemotherapy cardiotoxicity in patients with cancer

Ultrasound assessment of radiochemotherapy cardiotoxicity in patients with cancer

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2200061183
Enrollment
Unknown
Registered
2022-06-15
Start date
2022-06-01
Completion date
Unknown
Last updated
2023-03-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cancer

Interventions

Gold Standard:Cardiotoxicity was defined as decrease in LVEF >= 10% to = 5% decrease to < 55% symptomatic at least one MUGA scan or echocardiogram
Index test:LVEF&#32
by&#32
(M-mode&#32
Simpson&#32
tracking)/ECG

Sponsors

Sichuan Cancer Hospital Institute
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 100 Years

Inclusion criteria

Inclusion criteria: 1. Pathologically diagnosed as primary malignant tumors of the breast cancer; 2. The above-mentioned diagnosed patients have been prescribed the treatment plan by the clinician including chemotherapy, radiotherapy, secretory therapy, targeted therapy, immunotherapy; 3. Sign the informed consent form, and they have to underwent ultrasound imaging before therapy, in the short and long term after radiotherapy.

Exclusion criteria

Exclusion criteria: 1. Patients who have not completed the therapy cycle; 2. Patients who do not agree to follow-up examinations or who cant answer or die during the follow-up period; 3. Patients whose tumors are not primary; 4. patients with skin ulceration cannot be applied with coupling agent patient or take us examination.

Design outcomes

Primary

MeasureTime frame
LVEF;ECG;

Secondary

MeasureTime frame
heart chamber size;

Countries

China

Contacts

Public ContactMan Lu
graceof@163.com+86 18908190051

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026